Physician profile
Edward C Mader
NPI 1447273362
$1,640.38
in general payments reported to CMS, 2019-2025
20 companies · $273 in 2025
The $273 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $579 · 2020: $53.23 · 2021: $19.41 · 2023: $590 · 2024: $125 · 2025: $273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $988.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $988.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $565.65 | 2023-2025 | Briviact, Fintepla, Nayzilam |
| Teva Pharmaceuticals USA, INC. | $226.48 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $168.73 | 2019-2020 | |
| Abbvie INC. | $93.90 | 2023 | |
| Livanova USA, INC. | $67.99 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $64.35 | 2023-2025 | Ultomiris, Soliris |
| Biogen, INC. | $54.09 | 2025 | Leqembi |
| Novartis Pharmaceuticals Corporation | $53.26 | 2019 | |
| Octapharma USA, INC. | $51.99 | 2023 | Panzyga |
| Csl Behring | $46.95 | 2024 | Hizentra |
| Eisai INC. | $40.92 | 2019 | |
| Adamas Pharmaceuticals, INC. | $40.39 | 2019-2020 | |
| Sarepta Therapeutics, INC. | $29.91 | 2023 | Exondys 51 |
| Allergan, INC. | $24.33 | 2019 | |
| Horizon Therapeutics Plc | $21.33 | 2023 | Uplizna |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $20.84 | 2025 | Uplizna |
| Takeda Pharmaceuticals U.S.A., INC. | $20.53 | 2023 | Gammagard |
| Sk Life Science, INC. | $18.81 | 2024 | |
| Avanir Pharmaceuticals, INC. | $16.28 | 2019 | |
| Genzyme Corporation | $13.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Mader listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.